Cutter G - Search Results

1

Mortality in patients with multiple sclerosis.

Scalfari A, Knappertz V, Cutter G, Goodin DS, Ashton R, Ebers GC. Scalfari A, et al. Among authors: cutter g. Neurology. 2013 Jul 9;81(2):184-92. doi: 10.1212/WNL.0b013e31829a3388. Neurology. 2013. PMID: 23836941 Free PMC article. Review.

2

Clinical outcomes assessment in multiple sclerosis.

Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E. Rudick R, et al. Among authors: cutter g. Ann Neurol. 1996 Sep;40(3):469-79. doi: 10.1002/ana.410400321. Ann Neurol. 1996. PMID: 8797541 Review.

3

Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force.

Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E. Rudick R, et al. Among authors: cutter g. Ann Neurol. 1997 Sep;42(3):379-82. doi: 10.1002/ana.410420318. Ann Neurol. 1997. PMID: 9307263

4

Development of a multiple sclerosis functional composite as a clinical trial outcome measure.

Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, Ellison GW, Lublin F, Miller AE, Rao SM, Reingold S, Thompson A, Willoughby E. Cutter GR, et al. Brain. 1999 May;122 ( Pt 5):871-82. doi: 10.1093/brain/122.5.871. Brain. 1999. PMID: 10355672

5

Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life.

Miller DM, Rudick RA, Cutter G, Baier M, Fischer JS. Miller DM, et al. Among authors: cutter g. Arch Neurol. 2000 Sep;57(9):1319-24. doi: 10.1001/archneur.57.9.1319. Arch Neurol. 2000. PMID: 10987899

6

Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS.

Rudick RA, Cutter G, Baier M, Fisher E, Dougherty D, Weinstock-Guttman B, Mass MK, Miller D, Simonian NA. Rudick RA, et al. Among authors: cutter g. Neurology. 2001 May 22;56(10):1324-30. doi: 10.1212/wnl.56.10.1324. Neurology. 2001. PMID: 11376182

7

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Jak AJ, Kniker JE, Kooijmans MF, Lull JM, Sandrock AW, Simon JH, Simonian NA, Whitaker JN. Cohen JA, et al. Among authors: cutter gr. Arch Neurol. 2001 Jun;58(6):961-7. doi: 10.1001/archneur.58.6.961. Arch Neurol. 2001. PMID: 11405811 Clinical Trial.

8

Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite.

Balcer LJ, Baier ML, Cohen JA, Kooijmans MF, Sandrock AW, Nano-Schiavi ML, Pfohl DC, Mills M, Bowen J, Ford C, Heidenreich FR, Jacobs DA, Markowitz CE, Stuart WH, Ying GS, Galetta SL, Maguire MG, Cutter GR. Balcer LJ, et al. Among authors: cutter gr. Neurology. 2003 Nov 25;61(10):1367-73. doi: 10.1212/01.wnl.0000094315.19931.90. Neurology. 2003. PMID: 14638957

9

Effect of relapses on development of residual deficit in multiple sclerosis.

Lublin FD, Baier M, Cutter G. Lublin FD, et al. Among authors: cutter g. Neurology. 2003 Dec 9;61(11):1528-32. doi: 10.1212/01.wnl.0000096175.39831.21. Neurology. 2003. PMID: 14663037

10

Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.

Baier ML, Cutter GR, Rudick RA, Miller D, Cohen JA, Weinstock-Guttman B, Mass M, Balcer LJ. Baier ML, et al. Among authors: cutter gr. Neurology. 2005 Mar 22;64(6):992-5. doi: 10.1212/01.WNL.0000154521.40686.63. Neurology. 2005. PMID: 15781814 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

815 results

Search Page